Articles tagged with Anticoagulants
A UNC Charlotte-led team has invented a new biomolecular anticoagulant platform that holds promise as a revolutionary advancement over current blood thinners. The technology uses programmable RNA-DNA fibers to prevent blood clotting as needed, then be swiftly eliminated from the body.
A new study reveals racial and socioeconomic inequalities in the prescribing of oral anticoagulants to reduce stroke risk in people with atrial fibrillation. Patients from black and other ethnic minorities, as well as those living in deprived areas, are less likely to receive medication.
Patients with a history of unprovoked venous thromboembolism who stop treatment after negative D-dimer tests experience an eight-fold increased risk of recurrence compared to those on low-dose apixaban. Low-dose apixaban was found safe and effective for these patients
A retrospective case-control study found no significant difference in traumatic intracranial hemorrhage frequency between adult patients on antithrombotic therapy and those not on the therapy. However, hematoma expansion occurred more frequently in patients on antithrombotic therapy.
Researchers have discovered that bioprosthetic heart valve patients develop an immune response against foreign sugars in the valves, leading to calcification and deterioration. By genetically engineering these sugars out of the valves, durability can be increased, offering a potential solution for patients.
A retrospective cohort study of patients with atrial fibrillation and diabetes found that non-vitamin K antagonist oral anticoagulants (NOAC) were associated with a lower risk of diabetes complications and mortality than warfarin. The study suggests that NOAC may be a better therapeutic choice for this patient population.
A new study from USF Health reveals that activated protein C may help improve aging patients' tolerance to reperfusion injury, a potentially adverse effect of treatment for ischemic heart disease. The researchers suggest that drugs derived from APC may limit ischemia and reperfusion-induced heart damage.
A recent University at Buffalo-led study found that nearly 1 in 7 COVID patients in ICU experienced severe bleeding when given full-dose blood thinners. The research compared the safety and effectiveness of two blood clot treatment strategies, finding that a smaller dose was equally effective but carried less bleeding risk.
A new study published in Mayo Clinic Proceedings found that direct oral anticoagulants significantly decrease cancer-associated venous thrombosis recurrence without increasing bleeding. The study involved 2,894 patients and showed a 41% decrease in thrombosis recurrence with direct oral anticoagulants compared to parenteral dalteparin.
A new study published in the Canadian Journal of Cardiology found that frail patients with atrial fibrillation are under-prescribed for direct oral anticoagulants (DOACs), a safer alternative to traditional warfarin treatment. Despite needing DOACs most, these patients are less likely to receive them than non-frail patients.
The NUS Medicine team developed a series of thrombin inhibitors from tick transcriptome-derived sequences, offering potent anticoagulants with reduced bleeding risks. These next-generation anticoagulants hold promise for treating conditions like heart attacks, strokes, and SARS-CoV-2 infections.
Researchers compared milvexian with enoxaparin for prevention of blood clots in knee replacement surgery patients. Milvexian resulted in better clot protection without increased bleeding risk. The study suggests a safer oral anticoagulant alternative for preventing blood clots.
A study led by Oliver Königsbrügge and Cihan Ay found that current anticoagulants used to prevent strokes in dialysis patients with atrial fibrillation do not provide adequate protection. The VIVALDI study highlights the need for improved stroke prevention methods in this group.
A study published in Cardiovascular Research found that an anticoagulant medication can improve the survival of COVID-19 patients and shorten the duration of active SARS-CoV-2 infection. The medication, low-molecular-weight heparin, also curtails viral persistence by inhibiting the virus's ability to bind to cells.
A clinical trial of 465 patients found that administering heparin in therapeutic doses reduced mortality from COVID-19 by 78%, with benefits only observed when administered between seven and 14 days after symptom onset. The study suggests that timing is crucial for treatment efficacy.
A University of Minnesota Medical School-led study found that patients on blood thinners before having COVID-19 were admitted less often to the hospital and had reduced deaths. The use of blood thinners also benefited hospitalized COVID-19 patients regardless of medication type or dose.
A recent study found that 26-45% of people with atrial fibrillation fail to adhere to their prescribed direct-acting oral anticoagulants due to cost and bleeding concerns. Researchers interviewed 42 adults who had stopped or reduced dosing, citing these reasons as major barriers to adherence.
The CAPTIVA trial will enroll 1,683 patients with symptomatic intracranial arterial stenosis and determine if two new prospective therapies are more effective than aspirin plus clopidogrel at reducing the risk of a second stroke. Intensive medical management and lifestyle modifications will also be provided to all patients.
A large-scale international study found that edoxaban is non-inferior to warfarin for efficacy in preventing adverse events, but led to higher bleeding complications. The trial suggests that treatment with edoxaban can be valuable in managing AF patients after TAVR, especially when a lower dose of edoxaban is used.
A study involving 2,200 patients found that therapeutic-dose anticoagulation improved survival rates among moderately ill COVID-19 patients. The treatment reduced the likelihood of needing cardiovascular respiratory organ support by 27% and increased chances of survival without such support by 4%.
A clinical trial shows that full-dose blood thinner treatment reduced the need for organ support and improved hospital outcomes in moderately ill COVID-19 patients. However, this benefit was not seen in critically ill patients requiring intensive care.
A new study found that nearly one-third of patients prescribed a direct oral anticoagulant were also taking aspirin without a clear reason, leading to an increased risk of bleeding events. The researchers emphasize the importance of consulting with doctors to determine if combination therapy is necessary for individual patients.
A study of over 56,000 patients found that new users of direct oral anticoagulants (DOACs) had lower risks for ischemic stroke or systemic embolism and major bleeding events compared to warfarin. DOACs were associated with greater effectiveness and fewer major bleeding events in adults with valvular atrial fibrillation.
Patients given prophylactic anticoagulants within 24 hours of admission with COVID-19 are less likely to die compared to those who don't receive them. The study found a significant reduction in mortality risk among hospitalized COVID-19 patients, with a relative risk reduction as high as 34%.
A large Swedish registry study found that DOAC use did not reduce the rate of hospitalisation, intensive care or fatality due to COVID-19. The study included over 100,000 patients with atrial fibrillation and over 350,000 individuals with cardiovascular disease.
Researchers found that rivaroxaban is comparable to warfarin in preventing events in patients with bioprosthetic mitral valves and atrial fibrillation. Rivaroxaban was also shown to be superior to warfarin for a subgroup of patients with recent mitral valve replacement.
A new study found that an educational mailing did not increase the uptake of stroke prevention drugs among patients with atrial fibrillation. The IMPACT-AFib trial involved over 47,000 patients and showed no significant difference in oral anticoagulant initiation between the intervention group and control group.
This observational study found a significant prevalence of lupus anticoagulant (LA) positivity among patients with COVID-19, indicating a potential link between LA and severe disease outcomes. The study's findings suggest that monitoring for LA positivity may be crucial in managing COVID-19 patients.
A new analysis found that fewer people with COVID-19 suffer from stroke compared to previous reports. However, strokes in patients with the virus tend to be more severe and have poorer outcomes.
Researchers found that a short-term diet high in fruits and vegetables significantly lowers markers for subclinical cardiac damage and strain in adults without preexisting cardiovascular disease. The DASH trial data suggests that increased consumption of potassium, magnesium, and fiber may partly explain the observed effects.
Researchers found that anticoagulants improved survival rates among COVID-19 patients in and out of the intensive care unit setting. Treatment with anticoagulants was associated with reduced mortality and longer hospital stays for ventilated patients.
Patients with atrial fibrillation who took oral anticoagulants alone after TAVR had a lower rate of bleeding complications without an increased risk of clotting-related complications. Oral anticoagulants alone were significantly less likely to suffer bleeding complications than those who took antiplatelet medication in addition.
A nationwide prospective cohort study found that adults taking Vitamin K antagonist medication (VKA) had a lower incidence of overall bleeding events compared to direct oral anticoagulants. However, the VKA group also experienced a significantly higher mortality rate over one year.
A study published in CMAJ found that prescribing anticoagulants in the emergency department for patients with atrial fibrillation increases their likelihood of long-term medication adherence. This practice is associated with improved stroke prevention outcomes, particularly among older adults.
A Finnish study uses GIS data to compare the costs of warfarin and direct oral anticoagulant therapies, finding that DOACs are more cost-effective for patients living far from INR sample collection points or requiring frequent monitoring. The researchers developed a geospatial model to determine market areas and costs for each therapy.
A US-led study found that anticoagulants for atrial fibrillation lose their effectiveness in older patients due to increased mortality from non-stroke causes. The study of nearly 15,000 AF patients aged 75+ found warfarin and apixaban were not beneficial after age 87 and 92, respectively.
A study found that nearly 98% of people prescribed apixaban, a common anticoagulant, use over-the-counter products, which can cause dangerous internal bleeding. Many patients lack knowledge of these interactions, highlighting the need for education and further research.
A study published in Journal of the American College of Cardiology shows that oral anticoagulant dabigatran slows Alzheimer disease progression in mice by improving cerebral circulation. The treatment reduces typical symptoms like inflammation and amyloid protein plaques.
Researchers found that cold snare polypectomy with continuous anticoagulant use does not increase bleeding risk, showing non-inferiority and even superiority over traditional methods. The study suggests that this procedure can be a safer alternative for patients taking blood thinners.
A large cohort study found a significant link between atrial fibrillation and an increased risk of dementia in elderly individuals, even those without a history of stroke. The study also showed that anticoagulant treatment may help mitigate this risk.
A study found that pharmacy closures are associated with declines in cardiovascular medication adherence among adults 50 or older. The analysis of prescription claims revealed a significant decrease in adherence to statins, β-blockers, and oral anticoagulants following pharmacy closure.
The updated guidelines now prefer non-vitamin K oral anticoagulants (NOACs) over warfarin for reducing stroke risk in patients with atrial fibrillation. NOACs have been shown to be safer and potentially more effective at preventing blood clots than warfarin, according to new scientific studies.
A Vanderbilt University Medical Center study shows that combining PPIs with oral anticoagulants reduces the risk of gastrointestinal bleeding by 34% among high-risk patients. This protection is most significant for those taking warfarin, with a hospitalization rate reduced from 4% to 2.8% per year.
A new study found racial disparities in the use of oral anticoagulants among Black patients with atrial fibrillation. Compared to white and Hispanic patients, Black patients had lower odds of receiving oral anticoagulants, particularly newer versions.
A new biosensor device uses gold nanostructures to detect the presence of anticoagulant drugs like Sintrom, enabling personalized therapy adjustments. This technology has significant potential for patients with cardiovascular diseases or thromboembolic disorders, who often face risks associated with incorrect medication dosing.
A new study found that combining oral anticoagulants with antiplatelets worsened outcomes in patients with newly diagnosed atrial fibrillation, especially those without coronary artery disease or peripheral artery disease. This challenges the use of combined therapy in these patients.
A new study found that using oral anticoagulants for 45 days after hospital discharge reduced the rate of non-fatal blood clots in medically ill patients. The trial, MARINER, showed no increase in major bleeding risk while offering protection against non-fatal blood clots.
A catheter-based procedure to close a type of 'hole in the heart' is strongly recommended for patients under 60 with a history of stroke, reducing the risk of future stroke more than antiplatelet therapy. The guideline also suggests anticoagulation over antiplatelet therapy for patients who value preventing strokes over risk of bleeding.
A study found that direct oral anticoagulants increase the risk of bleeding in patients with chronic kidney disease, highlighting the need for caution in their prescription. The findings suggest a higher risk of bleeding events compared to conventional anticoagulant warfarin use.
A University of Birmingham study found that GPs have improved diagnosis and treatment of atrial fibrillation, preventing 7,000 strokes annually. The proportion of patients prescribed anticoagulants increased from 35% to 75% between 2000 and 2016.
A recent study has found that people over 65 with chronic kidney disease and atrial fibrillation are at increased risk of stroke when taking blood thinners. The researchers estimate that half a million UK adults fall into this category, highlighting the need for cautious prescribing practices.
Researchers found that non-vitamin K antagonist oral anticoagulants are associated with reduced risk of adverse kidney outcomes in patients with atrial fibrillation. The study, published in the Journal of the American College of Cardiology, showed that about 1 in 4 patients taking these medications experienced significant kidney functi...
A study published in the European Heart Journal found that anticoagulant drugs used to prevent blood clots in atrial fibrillation patients also protect against dementia. The research analyzed data from over 444,000 patients and found a significant reduction in dementia risk among those taking anticoagulants.
Researchers from Kumamoto University found that different anticoagulants can form thrombi at varying rates, with some having faster clotting times than others. This study used a Total Thrombus-Formation Analysis System to analyze blood samples from patients taking warfarin or direct oral anticoagulants.
A study by the University of Birmingham reveals a significant treatment gap for patients with paroxysmal atrial fibrillation, where fewer are prescribed anticoagulants for stroke prevention. This results in preventable strokes, increased risk of death and disability.
A large observational study found that CT scans detect subclinical leaflet thrombosis in 12.1% of patients after aortic valve replacement, increasing the risk of transient ischemic attacks but not death or stroke. Oral anticoagulants reduced the risk of clots, while anti-platelet therapy was associated with increased risk.
A recent study found that uninterrupted treatment with dabigatran before, during, and after atrial fibrillation ablation significantly reduced the incidence of major bleeding events compared to warfarin. The trial showed a 5.3% reduction in major bleeding events, with major bleeds occurring in 1.6% of patients receiving dabigatran.
A recent study by University of Utah Health investigators found that up to three-quarters of surgery patients may not need anti-clotting medications, which could lead to harm. High-risk patients, however, showed significant benefits from the treatment.
A new analysis found that restarting dabigatran after a major bleeding event leads to lower recurrent hemorrhage risk compared to warfarin. Resuming anticoagulation therapy also reduced the likelihood of stroke-free survival, with dabigatran associated with nearly half the risk of another major bleeding event within one year.
A new study found that oral thrombin inhibitors (OTIs) encourage blood clotting under flowing conditions, increasing the risk of heart attack. The researchers suggest considering this when designing individual therapies for patients taking OTI drugs.